Overland Pharmaceuticals
Weijie Lan has a diverse and extensive work experience in the field of pharmaceuticals and research. Most recently, they held the position of VP, Cell Therapy Platform Research at Overland Pharmaceuticals. Prior to that, they served as a Senior Director at Walking Fish Therapeutics, Inc. and as a Senior Scientist II at AbbVie. Weijie also worked as a Scientist at Fate Therapeutics Inc and as a Postdoctoral Researcher at Ludwig Institute for Cancer Research, UC San Diego. They began their career as a Research Associate at the University of Virginia and gained experience in various research roles there, including participating in deciphering the epigenetic "histone code" at Dr. David Allis' lab. Overall, Weijie Lan has a solid background in pharmaceutical research and has held significant positions throughout their career.
Weijie Lan holds a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Genetics from the University of Virginia. In addition to their academic qualifications, they have obtained various certifications related to time management, resourcefulness, leadership, conflict management, and servant leadership from LinkedIn.
This person is not in any offices
Overland Pharmaceuticals
Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem. Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs. Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.